JP2019503386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019503386A5 JP2019503386A5 JP2018539087A JP2018539087A JP2019503386A5 JP 2019503386 A5 JP2019503386 A5 JP 2019503386A5 JP 2018539087 A JP2018539087 A JP 2018539087A JP 2018539087 A JP2018539087 A JP 2018539087A JP 2019503386 A5 JP2019503386 A5 JP 2019503386A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- inhibitor
- entinostat
- administered
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 23
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 9
- 229950005837 entinostat Drugs 0.000 claims 8
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- WWMASNYTEATYTC-KPKJPENVSA-N 4-(dimethylamino)-n-[[4-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide Chemical compound C1=CC(N(C)C)=CC=C1C(=O)NCC1=CC=C(\C=C\C(=O)NO)C=C1 WWMASNYTEATYTC-KPKJPENVSA-N 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 claims 1
- GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229950007812 mocetinostat Drugs 0.000 claims 1
- JKVNVKOVLBVYHQ-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]-4-pyrrolidin-1-ylbenzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CNC(=O)C1=CC=C(N2CCCC2)C=C1 JKVNVKOVLBVYHQ-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 claims 1
- 108010060597 trapoxin A Proteins 0.000 claims 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662288121P | 2016-01-28 | 2016-01-28 | |
| US62/288,121 | 2016-01-28 | ||
| PCT/US2017/015389 WO2017132536A1 (en) | 2016-01-28 | 2017-01-27 | Use of histone deacetylase inhibitors for enhancing immunotherapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019503386A JP2019503386A (ja) | 2019-02-07 |
| JP2019503386A5 true JP2019503386A5 (enExample) | 2020-03-05 |
Family
ID=58010402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539087A Pending JP2019503386A (ja) | 2016-01-28 | 2017-01-27 | 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10813919B2 (enExample) |
| EP (1) | EP3407913A1 (enExample) |
| JP (1) | JP2019503386A (enExample) |
| KR (1) | KR20180104122A (enExample) |
| CN (1) | CN108883179A (enExample) |
| AU (1) | AU2017211383A1 (enExample) |
| BR (1) | BR112018015291A2 (enExample) |
| CA (1) | CA3013047A1 (enExample) |
| IL (1) | IL260765A (enExample) |
| MX (1) | MX2018009247A (enExample) |
| RU (1) | RU2018130831A (enExample) |
| WO (1) | WO2017132536A1 (enExample) |
| ZA (1) | ZA201805066B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| KR102603681B1 (ko) | 2016-12-07 | 2023-11-17 | 아게누스 인코포레이티드 | 항체 및 이의 사용방법 |
| JP7348074B2 (ja) * | 2017-06-04 | 2023-09-20 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ | がん治療に対する個別化応答の予測方法およびそのキット |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
| JP2021511293A (ja) * | 2018-01-12 | 2021-05-06 | ビラクタ セラピューティクス，インク． | 細胞免疫療法で使用されるエピジェネティック修飾因子 |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| CN112569360A (zh) * | 2019-09-30 | 2021-03-30 | 中国医学科学院药物研究所 | 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用 |
| EP4385024A4 (en) | 2021-08-11 | 2025-06-25 | Oncohost Ltd | PREDICTING PATIENT RESPONSE |
| WO2024231293A1 (en) * | 2023-05-05 | 2024-11-14 | Euro-Celtique S.A. | Combinations for treating cancer |
| WO2024238811A2 (en) * | 2023-05-18 | 2024-11-21 | Avstera Therapeutics Corp. | Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same |
| WO2025155922A1 (en) * | 2024-01-19 | 2025-07-24 | The Trustees Of Indiana University | Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ600281A (en) | 2006-12-27 | 2013-03-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| US9987258B2 (en) * | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
| CN107614011A (zh) | 2015-03-20 | 2018-01-19 | 欣达克斯制药公司 | Hdac抑制剂和抗pd‑1抗体联合用于癌症的治疗 |
| WO2017035453A1 (en) * | 2015-08-26 | 2017-03-02 | The Johns Hopkins University | Compositions and methods for treating solid tumors |
| KR102631377B1 (ko) | 2015-09-02 | 2024-01-29 | 신닥스 파마슈티컬스, 인크. | 조합 요법을 위한 환자의 선별 |
-
2017
- 2017-01-27 AU AU2017211383A patent/AU2017211383A1/en not_active Abandoned
- 2017-01-27 US US16/072,659 patent/US10813919B2/en active Active
- 2017-01-27 EP EP17704370.0A patent/EP3407913A1/en not_active Withdrawn
- 2017-01-27 WO PCT/US2017/015389 patent/WO2017132536A1/en not_active Ceased
- 2017-01-27 MX MX2018009247A patent/MX2018009247A/es unknown
- 2017-01-27 RU RU2018130831A patent/RU2018130831A/ru not_active Application Discontinuation
- 2017-01-27 CN CN201780020460.2A patent/CN108883179A/zh active Pending
- 2017-01-27 JP JP2018539087A patent/JP2019503386A/ja active Pending
- 2017-01-27 KR KR1020187024674A patent/KR20180104122A/ko not_active Withdrawn
- 2017-01-27 BR BR112018015291A patent/BR112018015291A2/pt not_active IP Right Cessation
- 2017-01-27 CA CA3013047A patent/CA3013047A1/en not_active Abandoned
-
2018
- 2018-07-24 IL IL260765A patent/IL260765A/en unknown
- 2018-07-27 ZA ZA2018/05066A patent/ZA201805066B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019503386A5 (enExample) | ||
| RU2018130831A (ru) | Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии | |
| US12083119B2 (en) | Methods and compositions for treating viral or virally-induced conditions | |
| RU2012135396A (ru) | Способы лечения рака с применением ингибитора аутофагии на основе тиоксантона | |
| JP2021038228A5 (enExample) | ||
| AU741768B2 (en) | Method for treating and preventing heart failure and ventricular dilatation | |
| SA522433000B1 (ar) | مركبات فلورو ألكيل-أوكساديازول واستخداماتها | |
| Wada et al. | α-Keto amides as inhibitors of histone deacetylase | |
| JP2007519619A5 (enExample) | ||
| AU2006212772B2 (en) | Combination of organic compounds | |
| JP2009539862A5 (enExample) | ||
| JP2011516565A5 (enExample) | ||
| CY1109363T1 (el) | Υδροξαμικες ενωσεις ως θεραπευτικοι παραγοντες | |
| MXPA05012345A (es) | Composicion farmaceutica que contiene un ihnibidor de histona deacetilasa. | |
| JPWO2004017996A1 (ja) | 関節軟骨細胞外マトリクス分解阻害剤 | |
| JP2009521424A (ja) | 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤 | |
| PH12021552930A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| HUP0100998A2 (hu) | (2E)-5-amino-5-metil-hex-2-én-sav-N-metil-N-{(1R)-1-[N-metil-N-/(1R)-1-(metil-karbamoil)-2-fenil-etil/-karbamoil]-2-(2-naftil)-etil}-amid-sók, eljárás azok előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| BRPI0609915A2 (pt) | métodos para tratar aterosclerose | |
| RU2008107871A (ru) | Применение ингибиторов hdac для лечения миеломы | |
| AU2006311723A1 (en) | Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent | |
| EA201101305A1 (ru) | Лечение рака поджелудочной железы | |
| EP1458378A1 (en) | Amino acid derivatives useful for the treatment of alzheimer's disease | |
| HRP20150520T1 (hr) | Supstituirani 2-okso- i 2-tiokso-dihidrokinolin-3-karboksamidi kao modulatori kcnq2/3 |